   |
|||||
|
|||||
 |
 |
 |
 |
 |
 |
Discovery leads to HK’s first anti-cancer drug granted with US FDA IND |
||
|
Optometry study finds astigmatism prevalent among Hongkongers Rehabilitation sciences research raises awareness of "prospective" memory problem Discovery leads to HK’s first anti-cancer drug granted with US FDA IND PolyU is Number One in Shipping Research, Number Four in Port Research
|
PolyU jointly researched BCT-100 with Bio-Cancer Treatment International Limited (BCT) at the laboratory stage. Thereafter, BCT followed up on additional research and development. Submitted by BCT as its sole owner, BCT-100 has become Hong Kong’s first Investigational New Drug (IND) approved by the US Food and Drug Administration. Developed by Prof. Thomas Leung Yun-chung and Associate Professor Dr Thomas Lo Wai-hung of PolyU’s Department of Applied Biology and Chemical Technology, and Dr Paul Cheng Ning-man, the new drug works on the mechanism of arginine depletion for the treatment of liver cancer. This achievement is hailed as an important milestone in the development of bio-technology and pharmaceutical industry in Hong Kong.
|
  |